One result that stood out from the meta-analysis showed that BiP positivity was associated with a higher risk of recurrence, although only three studies [10,41,46] the besides IPO-P cohorts were included in this analysis (note that the study by Lee et al., 2011 [48], was not considered since RFS is calculated in a specific subpopulation of breast cancer patients treated with taxanes). The gene discussed is HSPA5; the disease is breast carcinoma.